Daily pill almost doubles survival time for pancreatic cancer patients in new trial

This drug can double survival time for pancreatic cancer patients

Daraxonrasib, a daily oral KRAS inhibitor, doubled median survival in advanced pancreatic cancer patients to 13.2 months versus 6.6 months for chemotherapy, in a 500-patient Phase III trial presented at ASCO 2026. With KRAS mutations driving 90%+ of pancreatic ductal adenocarcinomas, this validates targeted KRAS inhibition as a viable clinical pathway and signals a pipeline shift toward oncology precision medicine investments.